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Incretin hormones include glucagon- like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide 
(GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance, incretin-based 
therapies have become a new class of antidiabetic agents for the treatment of type 2 diabetes mellitus (T2DM). 
Recently, the links between neurodegenerative diseases and T2DM have been identified in a number of studies, 
which suggested that shared mechanisms, such as insulin dysregulation or insulin resistance (IR), may underlie 
these conditions. Therefore, the effects of incretins in neurodegenerative diseases have been extensively 
investigated. Protease resistant long-lasting GLP-1 mimetics such as lixisenatide, liraglutide and exenatide not 
only have demonstrated promising effects for treating neurodegenerative diseases in preclinical studies, but also 
have shown first positive results in AD and PD patients in clinical trials. Furthermore, the effects of other 
related incretin-based therapies, such as GIP agonists, DPP-IV inhibitors, oxyntomodulin (OXM), dual 
GLP-1/GIP and triple GLP-1/GIP/glucagon receptor agonists on neurodegenerative diseases have been tested in 
preclinical studies. Incretin-based therapies are a promising approach for treating neurodegenerative diseases.  
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Aside from nutrient digestion and assimilation, the human gastrointestinal tract (GIT) also has significant 
endocrine functions. To date, the most important endocrine function of the GIT relates to intestinal derived 
peptides, which are fundamentally involved in postprandial insulin release. This action is termed the “incretin 
effect”. Only two incretin hormones named glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP) fulfil the criteria of a true incretin hormone that stimulates glucose-induced 
insulin secretion of islet beta-cell, and GLP-1 and GIP may be responsible for up to 70% of postprandial insulin 
secretion (Baggio and Drucker, 2007). 
Type 2 diabetes mellitus (T2DM) is a chronic endocrine and metabolic disorder characterized by 
progressive hyperglycemia, pancreatic β-cell dysfunction and relative insulin deficiency, and insulin resistance 
in peripheral tissues (Brunetti et al., 2014). The increase of endogenous insulin secretion and reduction of 
insulin resistance are important targets for antidiabetic drugs. Studies found that the incretin effect is severely 
reduced in patients with T2DM, which involve deficiency of postprandial insulin secretion (Irwin and Flatt, 
2015). Thus, incretin-based therapies have become new class of antidiabetic drugs for treatment of T2DM for 
their promising action on insulinotropic secretion and improving insulin resistance (Irwin and Flatt, 2015). 
Currently, two classes of incretin-based therapies are available in the clinic: the GLP-1 receptor agonists and the 
dipeptidyl peptidase-IV (DPP-IV) inhibitors (Chen et al., 2015a). Moreover, other related incretin-based 
therapies, including GIP receptor agonists, oxyntomodulin (OXM), dual agonists and triagonist for incretin 
receptors, have showed improved treatment effects for T2DM in preclinical studies (Finan et al., 2013, Finan et 
al., 2015).  
Besides anti-hyperglycemic efficacy for T2DM, incretin hormones also promote proliferation/neogenesis 
of beta cells and prevent their apoptosis, which demonstrate the trophic factor activity of incretins (Kielgast et 
al., 2011). Moreover, incretin hormones also show additional properties, specifically neurotrophic activity and 
protective effect, in T2DM-associated neurodegeneration (Hamilton et al., 2011, Salcedo et al., 2012). Recently, 
studies investigating the effects of incretin-based therapy on neurodegenerative diseases have been published 
that show very promising results, and may indicate an alternative approach for treating these patients (Perry and 
Greig, 2004, Harkavyi and Whitton, 2010, Li et al., 2010b, Bak et al., 2011, Mossello et al., 2011, Sakurai, 2011, 
Luchsinger, 2012, Salcedo et al., 2012, Holscher, 2014a, c, Ji et al., 2016a). In this review, we will primarily 
discuss the progress of ongoing research on the protection of incretin-based therapy against neurodegenerative 
diseases.  
 
Insulin resistance and neurodegenerative diseases 
 
As a result of the aging population, neurodegenerative diseases such as Alzheimer s disease (AD), 
Parkinson’s disease (PD), Huntington’s disease (HD) and Amyotrophic lateral sclerosis (ALS) have been one of 
the biggest health problems worldwide. However, there is no treatment available to cure these diseases. Because 
neurons rely more on glucose metabolism than other cell types, bioenergetic deficits have been considered a 
common cause of neurodegenerative diseases (Cai et al., 2012). Recent pathological investigations have shown 
that neurodegenerative disorders are associated with impairments in the glucose metabolic pathways, and the 
incidence of AD, PD, and several other neurologic disorders appears to be higher in persons with T2DM, 
suggesting that shared mechanisms, such as insulin dysregulation or insulin resistance in the brain, may underlie 
these conditions (Freiherr et al., 2013, Holscher, 2014d).   
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Alzheimer’s disease (AD)  
AD is a progressive neurodegenerative disorder that affects daily living through memory loss and cognitive 
impairment and is characterized by the presence of amyloid plaques which are mainly composed of amyloid 
beta (Aβ) peptide, neurofibrillary tangles and neuronal loss in distinct brain regions, including neocortex and 
hippocampus. Aging, genetic and environmental factors contribute to its development and progression. Recently, 
the potential links between AD and T2DM have been identified in several studies (Ott et al., 1999, Kopf and 
Frolich, 2009, Holscher, 2014c). Both T2DM and AD are age-related chronic diseases. Some epidemiological 
investigations demonstrated that T2DM increases the risk of developing AD by approximately two-fold, and 
patients with AD are more likely to develop T2DM (Kopf and Frolich, 2009). Interestingly, AD shares some 
common features with T2D such as ageing related processes, degeneration, high cholesterol levels, metabolic 
disorders, Aβ aggregation (Ashraf et al., 2014), glycogen synthase kinase-3 (GSK-3) hyper activity (Gao et al., 
2012), deregulated tau protein phosphorylation (Takalo et al., 2014), blood vessel abnormalities, increased 
oxidative stress, increased inflammatory response, correlation with apolipoprotein E ɛ4 allele (To et al., 2011) 
and glyceraldehyde derived advanced glycation end products (Li and Holscher, 2007).  
Most notably, it has been shown that an impaired cerebral glucose metabolism is detected at early stages in 
AD (Cohen and Klunk, 2014), and brain levels of insulin and functional insulin receptors (IR) are lower in AD 
(Moloney et al., 2010, Talbot et al., 2012). Insulin signaling impairments have been documented in both the 
brains of AD patients and animal models (Moloney et al., 2010, Holscher, 2011, Long-Smith et al., 2013). In 
AD patients, brain insulin resistance also occurs independently of diabetes or peripheral insulin resistance, and 
molecular markers of insulin resistance co-localize with Aβ oligomers and tau inclusions in AD brains 
(Yarchoan et al., 2014), which suggest that brain insulin resistance is likely a consequence of Aβ pathology. It 
has already been shown that Aβ oligomers downregulate insulin receptors in primary cortical neurons (Zhao et 
al., 2008) and induce insulin resistance in cultured hippocampal neurons (Ma et al., 2009). Furthermore, brain 
insulin signaling is particularly important for learning and memory (Townsend et al., 2007, Freiherr et al., 2013), 
and provides a physiological defense mechanism against oligomer-induced synapse loss (De Felice et al., 2009), 
and furthermore protects neurons from accumulation of hyperphosphorylated tau (Escribano et al., 2010), 
suggesting that insulin resistance may contribute to cognitive deficits in AD. Therefore, some authors have even 
proposed AD as a “Type 3 diabetes mellitus” limited to central nervous system (CNS) (Lester-Coll et al., 2006), 
though insulin insensitivity in the AD brain is not linked to high glucose levels. Thus, targeting brain insulin 
signaling for the treatment of cognitive impairment and AD has now attracted much attention in the field of AD 
drug discovery (Holscher, 2014d, Chen et al., 2016). In a series of small clinical trials in patients with mild 
cognitive impairment/AD, nasal application of insulin or long-lasting insulin analogs showed improvements in 
memory tasks, cerebrospinal fluid biomarkers, and other key biomarkers (Freiherr et al., 2013, Holscher, 2014b). 
With brain insulin resistance, however, insulin itself may not be the best choice, as it enhances insulin resistance, 
and other drugs that improve insulin sensitivity may be a better choice (Holscher, 2014b).  
 
Parkinson’s disease (PD)  
Recently, studies have shown a link between T2DM and PD, another common chronic neurodegenerative 
disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta 
(SNpc) and the degeneration of projecting nerve fibers in the striatum (Xu et al., 2011, Aviles-Olmos et al., 
2013b). Both T2DM and PD are age-related chronic diseases. Clinical data analyses confirmed that an 8-30 
percentage of PD patients were diabetic, a significantly higher percentage compared to age matched controls 
(Hu et al., 2007, Miyake et al., 2010, Cereda et al., 2011). Furthermore, abnormal glucose tolerance has been 
reported in >50% of PD patients (Schernhammer et al., 2011). PD and diabetes also share several genetic 
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susceptibilities, such as single nucleotide polymorphisms in the growth factor signaling kinase gene Akt, which 
increase an individual’s risk for developing PD and diabetes (Xiromerisiou et al., 2008). Common pathways that 
link PD, diabetes, and inflammation have been identified by genome-wide transcriptome profiling (Moran and 
Graeber, 2008). A study has established that ida-1 (islet cell diabetic autoantigen) is an important modulator in 
Daf-2/Daf-16 insulin-like signaling pathway and possibly a common link between PD and diabetes (Fatima et 
al., 2014). Thus, some pathogenic processes may underlie both conditions, and insulin desensitisation may be a 
common mechanism.  
Recent studies have provided evidence that insulin desensitization may exist in PD. An earlier study had 
found that there is a loss of insulin receptor immunoreactivity in the SNpc neurons in PD, and a dysfunction of 
the insulin/insulin receptor system may precede death of the dopaminergic neurons (Moroo et al., 1994). 
Furthermore, increased IRS2 phosphorylation, a marker of insulin resistance, was found in the basal ganglia of 
the 6-hydroxydopamine (6-OHDA) lesion rat model of PD (Morris et al., 2008). Moreover, in a high-fat-diet rat 
model of early-stage T2DM, insulin resistance impairs nigrostriatal dopamine function, indicating that 
dopaminergic signalling is compromised in T2DM (Morris et al., 2011). The findings are consistent with 
another study which showed high-fat diet exacerbated MPTP-induced dopaminergic degeneration in mice 
(Bousquet et al., 2012). In addition, α-synuclein pathology of PD can be induced solely by increased high blood 
glucose in diabetic animal models (Fatima et al., 2014). Moreover, In preclinical studies, systemic 
administration of drugs for T2DM, such as insulin (Holscher, 2014d), rosiglitazone (Schintu et al., 2009), and 
metformin (Patil et al., 2014), significantly attenuate pathological manifestations, including the loss of SNpc 
neurons and the striatal dopaminergic fibers, microglial activation, or the expression of pro-inflammatory 
cytokines. In light of these recent findings, a hypothesis has emerged that suggests that mitochondrial 
dysfunction, endoplasmic reticulum stress, inflammation, and alterations in metabolism may lead to insulin 
resistance and, ultimately, to diabetes and/or neurodegeneration (Santiago and Potashkin, 2013) (Lima et al., 
2014). Hence, the treatment to improve insulin resistance for T2DM may be useful for PD patients (Athauda 
and Foltynie, 2016). 
 
Huntington's disease (HD)   
Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an increased number of 
CAG repeats in the HTT gene which codes huntingtin protein. Apart from neurological impairments, the disease 
is also accompanied by progressive weight loss and poor glycemic control (Aziz et al., 2007, Aziz et al., 2010). 
Clinical data showed that patients with HD develop diabetes mellitus (DM) approximately 7 times more often 
than matched control participants (Farrer, 1985). An early study reported that abnormal glucose tolerance and 
decreased insulin secretion exists in HD (Podolsky and Leopold, 1977), and glucose metabolism is impaired in 
both brain and periphery (Petersen and Bjorkqvist, 2006, Powers et al., 2007). Moreover, Impaired glucose 
tolerance was showed in the R6/1 transgenic mouse model of HD (Josefsen et al., 2008), and transgenic mice 
eventually become diabetic (Hurlbert et al., 1999). Furthermore, impairment in insulin secretion capacity, a 
simultaneous decrease in insulin sensitivity, and an increase in the insulin resistance level was found in 
normoglycemic patients with HD (Lalic et al., 2008). Proteomic analysis of the human brain in HD indicated 
pathogenesis by molecular processes linked to T2DM (Schonberger et al., 2013). Although the “diabetic-like” 
condition in the HD mice is not improved by treatment with hypoglycemic agents (Hunt and Morton, 2005), 
antidiabetic treatment significantly prolonged the survival time of male HD mice (Ma et al., 2007). Hence, 
antidiabetic drugs may be protective agents for therapeutic intervention in HD patients.  
 
Amyotrophic lateral sclerosis (ALS)  
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Amyotrophic Lateral Sclerosis (ALS) is a devastating neurological disorder characterized by a selective 
degeneration of upper and lower motor neurons. Glucose intolerance and insulin resistance has been reported in 
a significant percentage of patients with ALS (Reyes et al., 1984, Perurena and Festoff, 1987, Pradat et al., 
2010), and insulin desensitization is related to disease severity (Harris et al., 1986). A recent systematic review 
also revealed that ALS was associated with diabetes mellitus (Lekoubou et al., 2014). However, whether there is 
a causal relationship between glucose homeostasis abnormalities and ALS is controversial (Sun et al., 2015). 
Moreover, two anti-diabetic drugs, metformin and pioglitazone, seem to have no beneficial effect in the 
SOD1(G93A) mouse model of ALS (Kaneb et al., 2011) and a clinical trial (Jawaid et al., 2014) (Dupuis et al., 
2012). However, another class of anti-diabetic drugs, GLP-1 analogs, has demonstrated neuroprotection against 
Kainate-induced excitotoxicity and trophic-factor withdrawal in SOD-1 in vitro and in vivo models (Lim et al., 
2010, Li et al., 2012b, Sun et al., 2013). 
 
Within this context, the use of antidiabetic drugs used to ameliorate hyperglycemia and insulin 
desensitization has been proposed as a potential therapy for several neurodegenerative diseases. Indeed, new 
strategies are being developed to inhibit pathologic hallmarks, such as the use of the incretin hormones as a new 




  GLP-1 expression in the periphery  
GLP-1 is a 30-amino acid peptide, which is derived from preproglucagon molecule and is secreted by 
intestinal endocrine epithelial L-cells. It is released in response to meal intake. The majority of circulating 
“bioactive GLP-1” is in the form of GLP-1(7-36)amide (Baggio and Drucker, 2007). GLP-1(7-36) has an 
extremely short half-life in the blood (<2 min) and is rapidly cleaved into its “inactive” truncated form, 
GLP-1(9-36)amide, by the ubiquitous proteolytic enzyme DPP-IV(Baggio and Drucker, 2007).   
The actions of GLP-1 are mediated by GLP-1R, a 7-transmembrane spanning protein that belongs to the 
class B1G-protein-coupled receptor family, which is highly expressed on islet beta cells (Doyle and Egan, 2007, 
Holscher and Li, 2010). By the binding with GLP-1R of islet, GLP-1 evokes robust insulin-releasing and 
antihyperglycaemic effects. GLP-1 also promotes beta-cell proliferation and islet cell neogenesis as well as 
inhibiting beta-cell apoptosis and alpha-cell glucagon secretion. GLP-1R is also expressed widely in the nonislet 
cells, including heart, intestine, immune cells, kidney, and brain, and exerts indirect metabolic actions. These 
actions include inhibiting gastric emptying, increasing insulin sensitivity in peripheral tissues, suppression of 
appetite and reducing bodyweight (Campbell and Drucker, 2013). In addition, GLP-1 also shows improving 
endothelial function, decreasing inflammation and cardioprotective role (Seufert and Gallwitz, 2014). 
 
GLP-1 analogues and T2DM 
Given this advantageous biological action profile in glucose homeostasis, GLP-1 is a potent T2DM 
treatment. However, the short half-life of native GLP-1 limits its application. To overcome this problem, GLP-1 
analogues resistant to degradation by DPP-IV have been developed by three different strategies. The first 
strategy exploits a naturally occurring protein, exendin-4 (originally isolated from the saliva of the lizard 
Heloderma suspectum), which activates the GLP-1R with equal potency as native GLP-1 (exenatide (Faludi et 
al., 2009) and lixisenatide (Petersen and Christensen, 2013)). The second strategy exploits the structure of native 
GLP-1, with a few amino acid alterations that protect the molecule from being degraded by DPP-4 (taspoglutide 
(Dong et al., 2011)). The third strategy is to slower absorption and to reduce renal elimination by fusion with 
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larger carrier molecules like albumin (albiglutide (Tomkin, 2009, Trujillo and Nuffer, 2014)) or Fc fragments of 
immunoglobulin G (dulaglutide (Scheen, 2016)), or by attachment of a fatty-acid side-chain which allows 
reversible binding to albumin (liraglutide (Vilsboll, 2009) and semaglutide (Lau et al., 2015)). Besides this, 
incorporation of the molecules in injectable microspheres (exenatide once-weekly) is a viable strategy to extend 
drug duration. Table 1 shows several novel enzyme-resistant, long-acting GLP-1 analogues which have been 
approved and are on the market as a T2DM treatment (Jendle et al., 2012), or which have shown good effects in 
preclinical and clinic trails. These GLP-1 agonists are currently used as second-line therapies in type 2 diabetes 
mellitus, or in triple therapy regimens, and are also applied for first-line use in the case of intolerance or 
contraindications to metformin(Inzucchi et al., 2015). Moreover, GLP-1 analogues have a favorable safety 
profile and a low risk of hypoglycemia (Nauck, 2011). 
  
GLP-1 in the brain  
Within the brain, a small amount of GLP-1 is produced in the nucleus of the solitary tract in the caudal 
brainstem (Merchenthaler et al., 1999, Salcedo et al., 2012, Ohshima et al., 2015). Besides these neurons, 
microglia also may express and secrete GLP-1, and expression and secretion are stimulated by cAMP and 
dependent on the microglial activation state (Kappe et al., 2012). Peripheral GLP-1 also can cross the 
blood-brain barrier into the brain, or communicate with the brain via sensory afferent vagal neurons (Hunter and 
Holscher, 2012, Cork et al., 2015). The GLP-1R is also expressed widely in the CNS, including the 
hypothalamus, cortex, hippocampus, striatum, substantia nigra and brain stem, as well as the subventricular 
zone (Merchenthaler et al., 1999, Hamilton and Holscher, 2009, Cork et al., 2015). Under normal physiological 
conditions, its expression is primarily confined to large output neurons, epitomized by pyramidal and dentate 
granule neurons as well as Purkinje cells, where, in particular, it localizes to dendrites and on or near synapses 
(Cork et al., 2015). 
By binding to GLP-1R in the brain, GLP-1 may act as an anorectic neurotransmitter, regulates glucose 
homeostasis, lowers core body temperature and plays a role in the activation of the central stress responses 
(Vrang and Larsen, 2010). Moreover, within the brain GLP-1 appears to have additional effects that are not 
directly related to glucose metabolism. Recent studies have demonstrated that exogenous administration GLP-1 
or its analogues can promote cell proliferation, neuronal differentiation and neurite outgrowth, and enhance 
synaptic plasticity, strengthen long-term potentiation (LTP), improve cognitive performance (Gault and 
Holscher, 2008a, Holst et al., 2011), in accord with GLP-1R over-expression mice exhibiting increased neurite 
growth and improved learning (During et al., 2003) and knockout with impaired memory formation (Abbas et 
al., 2009). In vitro studies have shown that GLP-1 or its analogues protected against nerve cell apoptosis 
induced by several neurotoxic substances including H2O2 (Perry et al., 2002a), glutamate (Perry et al., 2002b), 
iron (Perry et al., 2003), Aβ (Perry et al., 2003, Li et al., 2010a) and methyl glyoxal (Kimura et al., 2009, 
Sharma et al., 2013). Other authors have observed GLP-1R expression also on glial cells (microglia and 
astrocytes), proposing a role for them as modulators of CNS inflammation (Iwai et al., 2006).  
 
The effects of GLP-1 on neurodegenerative disease 
In view of the potent neurotrophic and neuroprotective actions of GLP-1, several enzyme-resistant, 
long-acting GLP-1 analogues had been tested in different animal models of AD. In the APP/PS1 AD mouse 
model, liraglutide (McClean et al., 2011, Long-Smith et al., 2013), lixisenatide (McClean and Holscher, 2014b), 
exendin-4 (Li et al., 2010a), Val(8)GLP-1 (Gengler et al., 2012), and geniposide (Zhang et al., 2015b), a 
GLP-1R agonist extracted from gardenia fruit, decreases desensitization of insulin receptor, soluble Aβ 
oligomers, amyloid plaque load, astrocytosis and inflammatory reactions. The treatment also prevents memory 
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impairments, synapse loss, and deterioration of synaptic plasticity in the hippocampus (Gault and Holscher, 
2008a, McClean et al., 2010, McClean and Holscher, 2014a). Furthermore, in an AD rat model induced by 
intrahippocampal injection of Aβ, liraglutide (Han et al., 2013) and Val(8)GLP-1(Wang et al., 2010, Wang et al., 
2013) activates cAMP signaling in the brain and protects the rats against the Aβ-induced impairments of spatial 
memory and deﬁcit of LTP in a dose dependent manner. In the rodent model of sporadic AD by 
intracerebroventricularly injection with streptozotocin (STZ), liraglutide (Xiong et al., 2013), exendin-4 (Chen 
et al., 2012), Val(8)GLP-1 (Li et al., 2012a) and geniposide (Gao et al., 2014) decrease hyperphosphorylation of 
tau and neurofilament proteins. In the P301L mouse model of tauopathy, liraglutide furthermore reduced the 
levels of tangles and hyperphosphorylated tau (Hansen et al., 2015). All in all, these experimental studies in AD 
animal models have found beneficial effects of GLP-1-based therapies on cognition, synaptic plasticity and 
metabolism of Aβ and tau protein phosphorylation.  
Besides better therapeutic potential for AD, long-acting GLP-1 analogues had been tested in several animal 
models of PD. In a rat model of PD induced by 6-OHDA injection into the brain, exendin-4 has shown 
protection of dopaminergic neurons in the substantia nigra and prevention of dopamine loss in the basal ganglia 
while preserving motor control (Bertilsson et al., 2008). Moreover, exendin-4 reverses biochemical and 
behavioral deficits in a pre-motor rodent model of PD with combined noradrenergic and serotonergic lesions 
(Rampersaud et al., 2012). Furthermore, some authors also found that MPTP-treated mice, another typical PD 
mice model, were protected by exendin-4 (Li et al., 2009), Val(8)GLP-1-glu-PAL(Zhang et al., 2015a), 
liraglutide (Liu et al., 2015a), lixisenatide (Liu et al., 2015a) and geniposide (Chen et al., 2015b) against 
nigrostriatal damage. Thus, GLP-1-based therapies may be used as a possible therapy for the motor and/or 
non-motor symptoms prominent in the early stages of PD.  
In addition, some studies also demonstrated the neuroprotective activity of GLP-1 in both cell culture and 
in vivo models of ALS. In NSC-19 neuroblastoma cells, exendin-4 elevated choline acetyltransferase (ChAT) 
activity, increased cell viability, and protected cells from H2O2-induced oxidative stress and 
staurosporine-induced apoptosis. Additionally, in both wild-type SOD1 and mutant SOD1 (G37R) stably 
transfected NSC-19 cell lines, which were more vulnerable to oxidative stress, exendin-4 protected against 
trophic factor withdrawal-induced toxicity. ALS mice (SOD1 G93A mutant mice) treated with exendin-4 
showed improved glucose tolerance and normalization of behavior. Furthermore, exendin-4 treatment attenuated 
neuronal cell death in the lumbar spinal cord; immunohistochemical analysis demonstrated the rescue of 
neuronal markers, such as ChAT, associated with motor neurons (Li et al., 2012b). Moreover, a study showed 
that Exendin-4 protects motor neurons against glucosamine-induced cytotoxicity by restoring cellular glucose 
uptake, glucokinase activity and intracellular ATP levels (Lim et al., 2010). Similarly, N-acetyl-GLP-1(7-34) 
amide (N-ac-GLP-1), a long-acting, N-terminally acetylated, C-terminally truncated analog of GLP-1, also 
showed therapeutic potential in primary motor neuron cultures derived from non-transgenic and SOD1-G93A 
ALS mice (Sun et al., 2013). Thus, these neuroprotective effects of exendin-4 and N-ac-GLP-1 support the 
concept that GLP-1 signaling is neuroprotective and may be a treatment strategy for ALS.      
Several studies demonstrated that exendin-4 ameliorated abnormalities in peripheral glucose regulation and 
suppressed cellular pathology in both brain and pancreas in a N171-82Q mouse model of HD. The treatment 
also improved motor function and extended the survival time of the HD mice (Martin et al., 2009, Martin et al., 
2012). These findings demonstrate that GLP-1 –based strategies may be a neuroprotective treatment strategy for 
HD.  
Additionally, the anti-inflammation function of GLP-1 may be protective in the treatment of 
neurodegenerative diseases. Studies showed that exendin-4 can prevent lipopolysaccharide (LPS)-induced 
cytokine and chemokine mRNA synthesis in both human and mouse monocytes (Arakawa et al., 2010) and also 
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reduces the increase of microvascular permeability induced by LPS (Dozier et al., 2009). The drug can also 
reduce TNF- cytokine release and protect hippocampal neurons in STZ injected rats (Solmaz et al., 2015). 
Clear effects of exendin-4 in reducing chronic inflammation in a stroke diabetic rat model was found in another 
study (Darsalia et al., 2012, Darsalia et al., 2014). Chronic inflammation was also reduced by exendin-4 in a 
Parkinson’s animal model (Kim et al., 2009). Another study also had displayed that liraglutide reduced 
pro-inflammatory cytokine levels and inhibited chronic inflammation response in the brain induced by exposing 
the brain to 6 Gy X-ray irradiation (Parthsarathy and Holscher, 2013). Furthermore, several GLP-1 analogues 
also showed anti-inflammation function in various AD and PD animal models (Li et al., 2009, McClean et al., 
2011). Thus, GLP-1 may be a suitable treatment for reducing the chronic inflammatory response in the brain 
found in several neurodegenerative conditions.   
Based on the very encouraging protective properties of GLP-1 analogues, and on the fact that such drugs 
are already on the market and have shown a good safety profile, several clinical trials have started to test the 
neuroprotective effects of exenatide or liraglutide in PD or AD patients (Holscher, 2014a). A recent open label 
pilot study by Aviles-Olmos and colleagues suggests that 12 months of treatment with exenatide improves 
motor and cognitive symptoms in PD patients (Aviles-Olmos et al., 2013a), and that the effect persists as long as 
12 months after termination of the treatment (Aviles-Olmos et al., 2014). A phase II clinical trial testing the 
once-weekly formulation of exendin-4 is currently ongoing. The drug liraglutide has been shown to protect the 
brain from the AD disease progression in an 18FDG-PET imaging study. The AD typical reduction of brain 
acitivity and energy utilization was prevented by liraglutide, indicating that the drug reversed the insulin 
resistance in the brain and normalized brain function (Gejl et al., 2016). A phase II clinical trial is currently 
ongoing (Holscher, 2014a). Thus, GLP-1 analogues show great promise to be helpful in treating a range of 
neurodegenerative disorders.  
 
Glucose dependent insulinotropic polypeptide (GIP) 
 
GIP expression in the periphery 
GIP is an endogenous 42 amino acid peptide hormone synthesized in and released from intestinal K-cells 
(Baggio and Drucker, 2007). GIP initially was named gastric inhibitory polypeptide, based on its ability to 
inhibit gastric acid secretion. However, subsequent studies revealed that GIP could also stimulate insulin 
secretion in animals and humans. Because the inhibitory effect of GIP on gastric acid secretion was seen only at 
pharmacologic doses, whereas its incretin action occurred at physiologic levels, GIP was renamed glucose 
dependent insulinotropic polypeptide to reflect its physiologic action yet retain the acronym (Dupre et al., 1973). 
In humans, basal circulating GIP levels range between 0.06 and 0.1 nmol/L, and increase to 0.2-0.5 nmol/L after 
a meal (Ross et al., 1977, Orskov et al., 1996). The half-life of intact biologically active GIP is less than 2 
minutes in rodents, approximately 7 minutes in healthy individuals and 5 minutes in patients with T2DM, 
respectively (Deacon et al., 2000). The amino-terminal Tyr1-Ala2 dipeptide of GIP (1-42) is removed producing 
the metabolite GIP(3–42) by DPP-IV which is ubiquitously expressed in mammalian tissues and organs (Kieffer 
et al., 1995). GIP in the blood circulation also is rapidly cleared through the kidney (Meier et al., 2004), and the 
liver also contribute to GIP extraction.  
GIP exerts its effects through binding to the GIP receptor (GIP-R), a member of the 
7-transmembrane-spanning, heterotrimeric G-protein-coupled receptor superfamily. The GIP-R is widely 
distributed in the pancreas, stomach, small intestine, adipose tissue, adrenal cortex, pituitary, heart, testis, 
endothelial cells, bone, trachea, spleen, thymus, lung, kidney, thyroid, and several regions in the CNS (Baggio 
and Drucker, 2007). Activation of GIP-R signaling is coupled to increases in cAMP and intracellular Ca
2+
 levels, 
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as well as activation of PI-3K, PKA, PKB, MAPK, and phospholipase A2 (Baggio and Drucker, 2007). By the 
binding with GIP-R of islet, GIP potently stimulates insulin secretion similar to its sister hormone GLP-1 (Kim 
et al., 2005). Besides its insulinotropic activity, GIP exerts a number of additional actions including promotion 
of growth (Trumper et al., 2001), survival (Trümper et al., 2002), differentiation and proliferation of the 
pancreatic beta-cell (Marenah et al., 2006). In addition, GIP possesses glucose-lowering extrapancreatic effects, 
including inhibition of hepatic glucose production, promotion of glucose uptake in isolated muscle, and 
reduction of hepatic insulin extraction (Seino and Yabe, 2013). GIP receptors have been localized to rodent and 
human α-cells, and GIP infusion also increased plasma levels of glucagon and enhanced glucose excursion 
during a meal test in subjects with T2DM (Chia et al., 2009). GIP also plays a role in adipocyte biology and 
lipid metabolism, including increase of lipoprotein lipase, stimulation of lipogenesis, enhancement of fatty acid, 
augmentation of insulin-induced fatty acid incorporation and inhibition of both glucagon- and 
adrenergic-receptor-mediated lipolysis (McIntosh et al., 2009), which ensures efficient deposition of fat in body 
stores. Moreover, GIP receptors are expressed by osteoclastic cells in bone, activation GIP receptors may 
promote bone formation in mice (Bollag et al., 2001, Tsukiyama et al., 2006, Zhong et al., 2007, Nissen et al., 
2014). GIP-receptor mRNA has been detected in the rat adrenal cortex. GIP exerts a moderate stimulatory effect 
on basal glucocorticoid secretion (Mazzocchi et al., 1999).  
 
Modification of GIP analogues 
Notably, the unfavourable pharmacokinetic profile and the weak biological effects of native GIP limit its 
effectiveness in the clinic. To overcome this, longer-acting GIP agonists exhibiting enzymatic stability and 
enhanced bioactivity have been generated. Due to enzymatic degradation in vivo by DPP IV, the most specific 
pharmacological approach for GIP would be modification at the N-terminus to disrupt DPP IV-mediated 
degradation. In addition, for being rapidly cleared through the kidney (Meier et al., 2004), it also is an 
alternative approach by binding with fatty acid derivatization or polyethylene glycol (PEG) to delay renal 
extraction of GIP. Indeed, it has been shown that these modified GIP analogues are not cleaved by DPP-IV, 
resulting in enhanced potency in vitro and greater insulinotropic and antihyperglycaemic activities in an animal 
model of T2DM compared to the native peptide (Irwin and Flatt, 2009).  
1.Several novel Tyr1-modified GIP analogues have been developed, including N-acetyl-GIP (Ac-GIP), 
N-pyroglutamyl-GIP (pGlu-GIP) (O'Harte et al., 2002), N-Fmoc-GIP (where Fmoc is 
9-fluorenylmethoxycarbonyl), N-palmitate-GIP (Gault et al., 2002), N-gluticol-GIP(Green et al., 2005) (O'Harte 
et al., 1999) (O'Harte et al., 2000).  
2. A series of Ala2-substituted GIP analogues has been synthesised, including (Abu2 (2-aminobutyric 
acid))GIP, (Sar2(2-sarcosine))GIP (Gault et al., 2003b), (Gly2)GIP(Gault et al., 2003a), (Ser2)GIP(Gault et al., 
2003a) and (d-Ala2)GIP (Hinke et al., 2002).  
3. By binding through fatty acid derivatization in C-terminal to delay renal extraction of GIP, several 














PAL) (Irwin et al., 2005b) and (d-Ala2)GIP-glu-PAL(Li et al., 2016).  
4. Through conjugation with PEG to prolong the in vivo half-life of GIP, Gault et al design a novel 
C-terminal mini-PEGylation of GIP (GIP[mPEG]) (Gault et al., 2008). And dual modification of a shortened 
version of GIP, GIP(1–30) by N-terminal acylation and C-terminal PEGylation, had been generated (Salhanick 
et al., 2005).    
 
GIP and T2DM 
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Due to potent insulinotropic effect of GIP, GIP may be promising as an attractive agent for the treatment of 
T2DM. On this point, however, there are a lot of disagreements. On the one hand, majority authors deem that 
GIP was not suitable for T2DM patients. Because in most T2DM patients, the secretion of GIP is near normal, 
but its effect on insulin secretion, particularly in the late phase is severely impaired. A study found that β cell 
GIP-R is transcriptionally upregulated by PPAR-γ, and GIP-R mRNA transcripts are reduced in islets from 
PPAR-γ -/- mice, potentially linking glucotoxicity to reduced PPAR-g activity and decreased GIP-R expression 
(Gupta et al., 2010). Hence, it seems obvious that there is a resistance to the insulinotropic action of native GIP 
in T2DM patients. Moreover, in a clinical trial, although GIP induced an early postprandial increase in insulin 
levels, GIP also induced an early postprandial augmentation in glucagon, a significant elevation in late 
postprandial glucose, and a decrease in late postprandial GLP-1 levels (Chia et al., 2009). With a concomitant 
increase in glucagon, the glucose-lowering effect of GIP was lost. Native GIP infusion further worsened 
hyperglycemia postprandially, most likely through its suppressive effect on GLP-1. Thus, these findings make it 
unlikely that GIP or GIP-R agonists will be useful in treating the hyperglycemia of patients with T2DM. 
Furthermore, some author has proposed using GIP receptor antagonism to treat T2DM patients (Gault et al., 
2005) (Sparre-Ulrich et al., 2016) and antagonizing GIP action may be a good therapeutic strategy for diabetes 
related obesity.  
On the other hand, recent studies support the application of GIP in treatment of T2DM patients (Finan et al., 
2016). A study has shown that the reduction of hyperglycaemia with insulin in T2DM subjects restores 
GIP-stimulated insulin secretion (Hojberg et al., 2009). Furthermore, the administration of sulphonylurea to 
induce KATP channel closure has been shown to ameliorate the impaired insulinotropic effect of GIP in patients 
with T2DM. Overall, this work suggests that the augmentation of GIP action is an appropriate goal for the 
treatment of T2DM, especially in combination with other glucose-lowering drugs (Irwin and Flatt, 2009). GIP 
overexpressing Tg mice demonstrated enhanced β-cell function, resulting in improved glucose tolerance and 
insulin sensitivity, they exhibited reduced diet-induced obesity. Reduced adiposity in GIP Tg mice was 
associated with decreased energy intake, involving overexpression of hypothalamic GIP. Together, these studies 
suggest that, in the context of over-nutrition, transgenic GIP overexpression has the potential to improve hepatic 
and adipocyte function as well as glucose homeostasis (Kim et al., 2012).  
To date, there are limited clinical data regarding GIP-based therapeutics in T2DM. Thus, more detailed 
clinical trials with large cases are needed to discover the true therapeutic promise of GIP-related peptide drugs.   
 
The effects of GIP on neurodegenerative diseases 
In the central nervous system, GIP is expressed in neurons and acts as a neurotransmitter, and GIP-R are 
also found in multiple brain regions, including the olfactory bulb, hippocampus, cerebellum, cerebral cortex, 
amygdala, substantia nigra, thalamus, hypothalamus, and brainstem (Nyberg et al., 2005, Nyberg et al., 2007). 
Recent studies have shown that application of stable GIP analogues such as D-Ala2-GIP or Pro3-GIP by 
peripheral administration can cross the BBB, and activation of the GIP-R leads to proliferation of neuronal 
progenitor cells (Holscher, 2014c). Therefore GIP may contribute to neurogenesis. GIP not only has 
growth-factor like properties in the brain, but also modulates synaptic activity. GIP prevented the detrimental 
effects of Aβ on synaptic plasticity (LTP) in the hippocampus (Gault and Holscher, 2008b) and on spatial 
learning and memory during the water maze task (Figueiredo et al., 2011). Furthermore, GIP has been shown to 
promote axonal regeneration after sciatic nerve injury (Buhren et al., 2009). In our previous study, chronic 
injection of D-Ala2GIP enhanced memory formation, synaptic neurotransmission (LTP) in the hippocampus, 
and progenitor cell proliferation in the dentate gyrus of wild type (WT) mice and mice on a high-fat diet without 
inducing adverse side effects (Porter et al., 2011, Faivre et al., 2012). Moreover, D-Ala2GIP can improve 
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cognitive function and prevent deficits of learning and memory in APP/PS1 transgenic mice, and reduces the Aβ 
plaque load and neuro-inflammation in the brain. Synaptic plasticity and synapse numbers were also normalized 
by the drug (Duffy and Holscher, 2013, Faivre and Holscher, 2013b, a). In our other study, the results 
demonstrate that treatment with D-Ala2-GIP-glu-PAL significantly inhibits MPTP-induced Parkinsonism-like 
behaviour of mice. D-Ala2-GIP-glu-PAL also reduces MPTP-induced damage in the dopaminergic neurons in 
mice model. Moreover, neuroprotective activity of D-Ala2-GIP-glu-PAL may, at least partially, result from 
increasing CREB-mediated Bcl-2 expression to prevent apoptosis and from the reduction of chronic 
neuro-inflammation (Li et al., 2016). Growth factor like agents such as long-acting GIP analogues hold promise 
of novel treatments that not only improve the symptoms but prevent the neurodegenerative processes underlying 
PD. Overall, these properties make GIP analogues a promising target for the development of novel treatments of 




DPP-IV, also known as adenosine deaminase complexing protein 2 (ADCP2), adenosine deaminase 
binding protein (ADABP), TP103 protein, and T cell activation antigen CD26, is a serine peptidase found in 
numerous sites, including the kidney, intestinal brush-border membranes, hepatocytes and vascular endothelium. 
In addition, DPP-IV is also expressed on a specific set of T lymphocytes and is thought to contribute to T-cell 
activation and proliferation. Solubilized DPP-IV is also found in body fluids such as blood plasma and 
cerebrospinal fluid. DPP-IV can selectively cleave off the N-terminal dipeptides from peptides with proline or 
alanine in the second amino acid position (Lambeir et al., 2003). As discussed above, this enzyme activity of 
DPP-IV has been implicated in the regulation of the biological activity of the insulinotropic peptides GLP-1 and 
GIP. In contrast, DPP-IV inhibition was demonstrated to protect GLP-1 and GIP from degradation, again 
resulting in enhanced insulinotropic activity of GLP-1 and GIP (Deacon et al., 2001). DPP-IV has other key 
substrates such as IGF-1 and other growth factors (Mentlein, 1999). 
 
DPP-IV inhibitor and T2DM  
A series of preclinical experiments and clinical trials have demonstrated that DPP-IV inhibitors are 
effective in enhancing endogenous levels of GLP-1 and GIP, resulting in enhanced insulin secretion, improved 
glucose tolerance and pancreatic islet cell function in animal models and patients of T2DM (Marguet et al., 
2000). These findings have resulted in eight commercially available DPP-4 inhibitors, including alogliptin 
(Nesina®, Vipidia®)(Keating, 2015, Takeda et al., 2016), anagliptin (Yang et al., 2015), gemigliptin 
(Zemiglo(®))(Kim et al., 2013, Jung et al., 2014), linagliptin (Forst and Pfutzner, 2012, Barnett, 2015), 
saxagliptin (Gault et al., 2015, Anderson et al., 2016), (Januvia(®), Xelevia™, Glactiv(®), Tesavel(®))(Garg et 
al., 2013, Plosker, 2014), teneligliptin (Nakamaru et al., 2015), and vildagliptin (Galvus®, Novartis AG) 
(Mikhail, 2008, Richter et al., 2008), being approved and entering into the clinic (Chen et al., 2015a). These 
DPP-IV inhibitors have good oral bioavailability and a relatively long duration of action in patients with T2DM. 
DPP-IV inhibitors may be used as monotherapy or in double or triple combination with other oral 
glucose-lowering agents such as metformin, thiazolidinediones, and sulfonylureas (Chen et al., 2015a). 
Long-term studies with the DPP-IV inhibitors in clinical development have, to date, proved these to be safe and 
well tolerated and not to be associated with adverse immune effects (Garg et al., 2013). Due to sustained 
DPP-IV enzyme inhibition and a long half-life, the majority of DPP-IV inhibitors are generally prescribed once 
a day. Therefore, DPP-IV inhibitors have become accepted in clinical practice due to their excellent tolerability 
profile, with a low risk of hypoglycemia, a neutral effect on body weight, and once-daily dosing (Chen et al., 





Fig. 2 chemical structures of clinically approved DPP-IV inhibitors (Chen et al., 2015a) 
 
The effects of DPP-IV inhibitors on neurodegenerative diseases   
Most DPP-IV inhibitors do not pass the blood-brain barrier, with some exceptions (Nassar et al., 2015), but 
DPP-IV inhibition increases circulated GLP-1and GIP, which are the blood brain barrier permeable ligands 
(Kastin et al., 2002). Thus, it is unsurprising to find CNS action of DPP-IV inhibitors. Recently, the 
neuroprotective properties of several DPP-IV inhibitors have been shown in cell cultures and animal models 
(Matteucci and Giampietro, 2015). Notably, saxagliptin recently showed an ameliorating efficacy in the 
STZ-induced AD model. Saxagliptin treatment improved hippocampal GLP-1 levels and memory retention, 
attenuated Aβ burden, tau phosphorylation, inflammatory markers (Kosaraju et al., 2013a). In a rat PD model 
induced by rotenone (ROT), saxagliptin prominently improved motor functions denoting antiparkinsonian 
efficacy via antioxidant, anti-inflammatory, antiapoptotic, neuroprotective and neurorestorative mechanisms 
(Nassar et al., 2015). In addition, saxagliptin also evoked neurogenesis indicated by BDNF enhancement. In 
addition, another DPP-IV inhibitor, vildagliptin, effectively restored neuronal IR function, increased GLP-1 
levels and prevented brain mitochondrial dysfunction, thus attenuating the impaired cognitive function caused 
by high-fat diet (HFD) (Pipatpiboon et al., 2013) (Pintana et al., 2013). Vildagliptin also restored the loss of 
hippocampus CA1 dendritic spines, which was associated with cognitive decline caused by HFD 
(Sripetchwandee et al., 2014). Furthermore, vildagliptin ameliorated cognitive deficits and pathology observed 
in the STZ-induced AD animal model (Kosaraju et al., 2013b). In the rat rotenone model of PD, vildagliptin 
blocked the receptor for advanced glycation end product（RAGE）/nuclear factor κB（NFκB） cascade,  
exerting a potential antiparkinsonian effect (Abdelsalam and Safar, 2015). Furthermore, administration of 
vildagliptin has significantly attenuated impairment of learning, memory, endothelial function, blood brain 
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barrier permeability and biochemical parameters induced by pancreatectomy (Jain and Sharma, 2015). In 
addition, sitagliptin also increased brain GLP-1 levels and decreased beta amyloid precursor protein (APP) as 
well as attenuated Aβ deposit in a transgenic mouse model of AD. Sitagliptin reduced the inflammation and 
nitrosative stress in the cerebral cortex (D'Amico et al., 2010). In rats with high-sucrose diet-induced metabolic 
syndrome (MetS), besides its well-known hypoglycemic action, sitagliptin may also have beneficial effects on 
hyperglycemia-induced vascular changes in an endothelium-dependent manner (Cicek et al., 2014). Sitagliptin 
significantly improved the metabolic parameters and decreased circulating and brain oxidative stress levels, and 
completely prevented brain and hippocampal mitochondrial dysfunction and equally improved the learning 
behaviors impaired by HFD-induced insulin-resistant rats (Pintana et al., 2013). Pterocarpus marsupium (PM, 
Fabaceae) and Eugenia jambolana (EJ, Myrtaceae) extracts have demonstrated the DPP-IV inhibitory properties 
(Kosaraju et al., 2014a), and PM and EJ extracts contain cognitive enhancers as well as neuroprotective agents 
against STZ induced pathology (Kosaraju et al., 2014b). Importantly, DPP-IV show neuroprotective effects 
independently of GLP-1 activity (Darsalia et al., 2016). Hence, these findings suggested the beneficial roles of 
DPP-IV inhibitors in AD and PD. Although mechanisms distinct from glycemic control alone have been claimed 
to account for protection against neuronal degeneration, the precise cellular mechanism by which DPP-IV 
inhibitors exert their neuroprotective effects remain unknown and need further be investigated (Matteucci and 
Giampietro, 2015).  
 
Oxyntomodulin (OXM)  
 
OXM is a 37-amino-acid peptide generated by post-translational processing of preproglucagon in the gut 
and is secreted postprandially from L-cells of the jejuno-ileum together with other preproglucagon-derived 
peptides including GLP-1(Bataille et al., 1982). Peripheral OXM administration reduces food intake and 
increases energy expenditure in rodents (Dakin et al., 2004) and humans(Wynne et al., 2006). Studies indicate 
that OXM activity at the GLP-1R is responsible for the reduction in food intake and activity at the glucagon 
receptor (GCGr) causes weight loss by increasing energy expenditure (Wynne et al., 2006, Kosinski et al., 2012). 
And it is notable that co-administration of GLP-1 and glucagon in humans can replicate the beneficial actions of 
OXM (Cegla et al., 2014). Hence, OXM is a natural agonist at both GCGr and the GLP-1R.  
 
OXM and T2DM 
The dual agonist properties of OXM add additional better effects than sole GLP-1R agonist for T2DM. 
OXM, like other GLP-1R agonists, stimulates cAMP formation and lowers blood glucose after both oral and ip 
glucose administration. OXM also directly stimulates insulin secretion from murine islets and INS-1 cells in a 
glucose- and GLP-1R-dependent manner. In addition, OXM enhances beta-cell function but does not inhibit 
gastric emptying in mice. Thus, OXM mimics some but not all of the actions of GLP-1R agonists in vivo 
(Maida et al., 2008). The difference of OXM may result from the activation of GCGr. It is generally recognized 
that glucagon increases blood glucose and plays an opposite effects different from insulin which decrease blood 
glucose. Thus, activation of GCGr seems to be a disadvantage for T2DM patients. However, this view has been 
questioned and challenged recently. A study has shown that transgenic mice overexpressing the GCGr in 
pancreatic beta-cells demonstrate increased insulin secretion and pancreatic beta-cell mass, with protection 
against impaired glucose tolerance following high fat feeding (Gelling et al., 2009). Moreover, a 4-week clinical 
study in obese subjects demonstrated that repeated subcutaneous administration of OXM was well tolerated and 
caused significant weight loss with a concomitant reduction in food intake(Wynne et al., 2005). As a result, by 
activating GLP-1 and GCGr, OXM may has superior weight loss and glucose lowering effects, compared to 
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single GLP-1R agonists, which support the role of OXM as a potential anti-obesity and antihyperglycemic 
therapy for T2DM patients.  
Despite their anti-diabetic and anti-obesity potential, OXM-based therapies have not yet reached the clinic, 
due to the susceptibility of the native hormone to enzymatic degradation. Native OXM is susceptible to 
degradation by the enzyme DPP-IV, which lead to the short in vivo half-life (Kervran et al., 1990). Thus, it is 
necessary to produce long-lasting analogues for clinical use. As discussed above, substitution of the naturally 
occurring -Ala at position 2 in incretin results in DPP-IV resistance, and C-terminal PEGylation and fatty acid 
derivatisation of incretins results in reduced renal clearance, by which several long-acting OXM analogues have 
been successfully developed (Muppidi et al., 2016). Indeed, a recent study of six novel OXM analogues has 
revealed that OXM-based peptides with specific N-terminal position 2 modifications are stable and show 
particular promise for the treatment of diabetes (Lynch et al., 2014). Moreover, a PEGylated analogue of OXM 
has also been designed and showed the long-lasting antihyperglycemic, insulinotropic and anorexigenic activity 
(Bianchi et al., 2013). In addition, Kerr et al also developed (d-Ser2)Oxm[mPEG-PAL], a novel OXM analogue 
with d-Ser at position 2 and C-16 palmitic acid conjugated via a mini-PEG linker at the C-terminus. And 
(d-Ser(2))Oxm[mPEG-PAL] displayed enhanced DPP-IV resistance compared to (d-Ser(2))OXM and native 
OXM. Acute administration of (d-Ser(2))Oxm[mPEG-PAL] and (d-Ser(2))Oxm reduced plasma glucose and 
food intake, whilst plasma insulin levels were elevated. Once-daily administration of 
(d-Ser(2))Oxm[mPEG-PAL] for 14 days to ob/ob mice decreased food intake, bodyweight, plasma glucose and 
increased plasma insulin. Furthermore, daily (d-Ser(2))Oxm[mPEG-PAL] improved glucose tolerance, 
increased glucose-mediated insulin secretion, pancreatic insulin content, adiponectin and decreased both visfatin 
and triglyceride levels (Kerr et al., 2010). In addition, several other forms of OXM including OXM6421 also 
showed similar effects (Pocai et al., 2009, Liu et al., 2010, Pocai, 2014). 
 
OXM in the brain 
Both OXM and GLP-1 are the anorexigenic gut hormones which are thought to physiologically regulate 
appetite and food intake in the brain (Vrang and Larsen, 2010). Most authors deemed that OXM and GLP-1 
regulate appetite and food intake by activation GLP-1 receptor in the brain. Direct administration of OXM into 
the arcuate nucleus inhibits feeding and this effect is pharmacologically blocked by prior administration of the 
GLP-1 receptor antagonist exendin(9-39) (Dakin et al., 2004). Also, arcuate nucleus administration of OXM is 
accompanied by a decrease in plasma ghrelin, an appetite stimulating hormone, which in part could explain the 
drop in fasting- induced feeding elicited by central GLP-1 activation (Patterson et al., 2009). Thus, it seems 
likely that OXM mediates this activity via GLP-1 receptors. This is also supported by findings in GLP-R KO 
mice that are unresponsive to centrally administered OXM (Baggio et al., 2004) while glucagon receptor KO 
mice are responsive (Baggio et al., 2004). However, some researchers also showed a difference between GLP-1 
and OXM activities. Administration of OXM resulted in a reduced rate of signal enhancement, reflecting in a 
reduction of neuronal activity in the arcuate, paraventricular, and supraoptic nuclei of the hypothalamus. 
Conversely, GLP-1 caused a reduction in signal enhancement in the paraventricular nucleus only and an 
increase in the ventromedial hypothalamic nucleus (Chaudhri et al., 2006). The results suggested that GLP-1 
and OXM may also act via different pathways to exert their anorexigenic effects. Previously studies have shown 
that GLP-1 acts mainly via the vagus nerve and the brainstem (Abbott et al., 2005). Different from GLP-1, 
OXM may act via different hypothalamic pathways (Parkinson et al., 2009). 
 
The effects of OXM on neurodegenerative diseases   
Up to now, only two studies in vivo showed neuroprotective potential of OXM. A study in high fat (HF) 
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mice (Pathak et al., 2015) showed that (dS(2))Oxm(K-γ-glu-Pal) or (dS(2))Oxm treatment significant decrease 
hippocampal oxidative damage, enhance hippocampal neurogenesis and improve hippocampal and cortical 
synaptogenesis, besides improving peripheral glucose homeostasis metabolic. The results demonstrate the 
potential of stable OXM analogues to improve metabolic function and enhance neurogenesis, synaptic plasticity, 
insulin signaling and exert protective effects against oxidative damage in hippocampus and cortex brain regions 
in HF mice. Another study in vivo showed that D-Ser2-oxyntomodulin (OXY) prevented or reversed motor 
impairment, reduction in tyrosine hydroxylase(TH) levels in the substantia nigra and basal ganglia and the 
reduction of the synaptic marker synapstophysin induced by MPTP (Liu et al., 2015b), which inidactes that 
OXM analogues may show promise as a novel treatment of PD. 
 
Dual agonist for GLP-1 and GIP receptors 
 
Dual agonists and T2DM 
Together, GIP and GLP-1 account for almost all of the well-established physiological incretin effect and 
have powerful insulin-releasing and glucose-regulatory properties. Stable GLP-1 mimetics have already been 
successfully adopted into the diabetic clinic, and GIP also offer promise as potential new classes of antidiabetic 
drugs. So, a combination therapy of GIP and GLP-1 or use of dual agonist peptides for treating T2DM has been 
proposed. Indeed, the clinical benefits of DPP-4 inhibitors clearly involves increased circulating levels of both 
incretin peptides (Gallwitz, 2013), which demonstrates that concomitant activation of GIP and GLP-1 receptors 
does appear to have promise for the treatment of T2DM. Moreover, recent a study also demonstrated that a 
combined preparation of the acylated GLP-1 (Liraglutide) and GIP peptides（N-AcGIP(Lys(37)Myr)）markedly 
improved glucose-lowering and insulinotropic properties in diabetic obesity compared with either incretin 
mimetic given individually (Gault et al., 2011). Therefore, dual agonist peptides for GLP-1R and GIP-R seem 
be more potent and beneficial than single receptor agonist for treatment T2DM (Irwin and Flatt, 2015).  
Interestingly, a new drug DA-JC1, which is a dual-GLP-1/GIP receptor agonist derived from an intermixed 
sequence of GLP-1 and GIP, had been engineered to activate both GLP-1 and GIP receptors with comparable 
affinity, and demonstrated enhanced insulinotropic and antihyperglycemic efficacy in animal models of diabetes 
relative to single GLP-1 agonist liraglutide (Finan et al., 2013). Moreover, the unimolecular dual incretin was 
DPP-IV-resistant, and maximized metabolic benefits and corrected two causal mechanisms of diabesity, 
adiposity-induced insulin resistance and pancreatic insulin deficiency (Finan et al., 2013). Furthermore, DA-JC1 
balanced and avoided the adverse gastrointestinal effects that typify selective GLP-1-based agonists while 
showing effects at much lower doses than liraglutide. 
 
The effects of dual agonist on neurodegenerative diseases  
Given double receptor activation, dual agonist seem be more beneficial than single GLP-1 or GIP agonist 
for improvement insulin resistance of neurodegenerative Diseases. Currently, there are 2 published studies 
which demonstrated the neuroprotective effects of DA-JC1 in the MPTP mouse model of PD by increasing 
expression of BNDF (Ji et al., 2016b), increasing the number of TH- positive neurons in the SN and reducing 
the activation of astroglia and microglia (Cao et al., 2016). In addition, DA-JC1 also showed more 
neuroprotective effects than a GLP-1 receptor agonist in transient focal cerebral ischemia in the rat (Han et al., 
2016). Hence, dual agonist for GLP-1R and GIP-R may be superior treatments for AD, PD and other 
neurodegenerative diseases based on their better insulinotropic activity and neurotrophic activity (Ji et al., 
2016a).  
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Triagonists for the GLP-1, GIP, and glucagon receptors 
 
Triagonists and T2DM 
GLP-1, GIP, and glucagon signaling are all comparatively important in terms of maintaining normal 
glycemic control (Cho et al., 2012). The G protein-coupled receptors (GPCRs) for GIP, GLP-1 and glucagon are 
emerging as targets to treat both hyperglycemia and obesity (Reimann and Gribble, 2016). Considering the 
evident therapeutic efficacy offered by dual agonist, single compounds with the ability to concurrently activate 
three regulatory peptide receptors could deliver even greater beneficial effects. Thus, there is now significant 
enthusiasm arising from designed peptides with the ability to concurrently modulate GIP, GLP-1 and glucagon 
receptor signaling.   
Recently, several triple-acting peptides have been designed and showed dramatic improvements in glucose 
homeostasis and overall metabolic control in high fat fed mice (Finan et al., 2015). Bhat et al designed a 
chemically modified peptide based on human glucagon with amino acid substitutions aligned to strategic 
positions in the sequence of GIP and named YAG-glucagon. YAG-glucagon is 
Y(1)-dA(2)-I(12)-N(17)-V(18)-I(27)-G(28,29)-glucagon. YAG-glucagon is a DPP-IV-resistant triple agonist of 
GIP, GLP-1 and glucagon receptors and exhibits potent glucose-lowering and insulinotropic actions in 
high-fat-fed mice (Bhat et al., 2013b). Besides, the first 11 N-terminal residues of OXM were substituted with 
the sequence of stable d-Ala(2)GIP molecules to generate a novel GIP-OXM peptide (d-Ala(2)GIP-OXM). The 
novel GIP-OXM hybrid peptide also acts through GIP, glucagon and GLP-1 receptors. Acute administration of 
d-Ala(2)GIP-OXM to HFF mice resulted in reduced plasma glucose, increased insulin concentrations and 
reduced body weight (Bhat et al., 2013a). In addition, others (Gault et al., 2013) also have constructed a series 
of novel GLP-1/GIP/glucagon hybrid peptides, through fusion of the key amino acid sequences of GLP-1, GIP, 
and glucagon known to be important for biological activity. The most effective peptide of them is 
[dAla2]GLP-1-glucagon-GLP-1 ([dA2]GLP/GcG). [dA(2)]GLP-1/GcG stimulated cAMP production in GIP, 
GLP-1, and glucagon receptor-transfected cells. Acute and chronic administration of [dA(2)]GLP-1/GcG all 
significantly lowered plasma glucose and increased plasma insulin in obese diabetic (ob/ob) mice. Furthermore, 
[dA(2)]GLP-1/GcG elicited a protracted glucose-lowering and insulinotropic effect in high fat-fed mice. 
[dA(2)]GLP-1/GcG decreased body weight, improved glucose tolerance and insulin sensitivity in high fat -fed 
mice. These findings showed that a unimolecular triple agonism strategy has potential to be the most effective 
pharmacological approach to reversing obesity and related metabolic disorders (Finan et al., 2015). Such 
balanced unimolecular triple agonism proved superior to any existing dual coagonists and best-in-class 
monoagonists to reduce body weight, enhance glycemic control and reverse hepatic steatosis. These dramatic 
effects may predominantly results from synergistic glucagon action to increase energy expenditure, GLP-1 
action to reduce caloric intake and improve glucose control, and GIP action to potentiate the incretin effect and 
buffer against the diabetogenic effect of inherent glucagon activity.  
 
Effects of triagonist on neurodegenerative Diseases 
In view of dual agonist having shown good promising for AD and PD, novel triagonists that activate 
GLP-1, GIP and glucagon receptors and that are currently being developed to treat type II diabetes (Finan et al., 
2015) should be tested in a variety of neurodegenerative disease models to investigate if they have superior 
properties to dual or single receptor agonists.  
 
Conclusion  
Neurodegenerative diseases and T2DM share common mechanisms, such as insulin resistance, which have 
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motivated the application of incretin hormones as a treatment of neurodegenerative diseases. Among 
incretin-based therapy, GLP-1 long-acting analogous not only have demonstrated promising effects in 
neurodegenerative diseases in preclinical studies, but also have shown first promising results in AD and PD 
patients in clinical trials. The effects of other related incretin-based therapies, such as GIP agonists, DPP-IV 
inhibitors, OXM, dual agonists and triagonists for incretin receptors on neurodegenerative diseases have been 
tested in preclinical studies. As novel dual or tri agonists appear to be superior to single agonists, dual or tri 
agonists are becoming the focus of research. Incretin-based therapies may show great promise of being helpful 
in treating a range of neurodegenerative disorders. However, clinical trials testing the effects in patients with 
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Fig. 1: Chemical modifications of GLP-1R agonists compared in head-to-head studies. The figure 
illustrates how different strategies have been applied to the GLP-1R agonists in order to provide 
prolonged action in the body. Grey circles indicate an altered amino acid sequence compared to 
native GLP-1. a. Exenatide once-weekly: the exenatide molecules are encapsulated in injectable 
microspheres. Abbreviations: rH-Albumin, recombinant human albumin; IgG Fc fragment, 
immunoglobulin fragment crystallized (Lund et al., 2014). 
 
 
Table 1:  GLP-1R agonists clinically approved or not yet approved(Lund et al., 2014) 
name the trade 
name 
half-life administration  company approved by 







Liraglutide Victoza® 11 to 15 h Subcutaneous 
once-daily 
Novo Nordisk EU, Japan,2009, 
USFDA, 2010 




Taspoglutide   Subcutaneous 
once weekly 
Ipsen/Roche   
Exenatide 
LAR 





Europe, 2011  
USFDA, 2012 















ly 90 h 
Subcutaneous 
once-weekly 
Eli Lilly Europe and 
USFDA, 2014 
semaglutide  165 h Subcutaneous 
once-weekly 
Novo Nordisk  
 
